Validation of a Circulating Tumor DNA‐Based Next‐Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing
暂无分享,去创建一个
Samuel V. Angiuoli | O. Elemento | A. Sboner | G. Cerqueira | Y. Houvras | J. Mosquera | N. Altorki | C. Sternberg | K. Holcomb | B. Faltas | E. Papp | S. Tagawa | A. Molina | D. Nanus | V. Guthrie | E. Hissong | M. Sigouros | K. Eng | D. Wilkes | R. Bareja | S. Beg | Noah Greco | Kentaro Ohara | J. Simmons | D. Nichol | J. Manohar | Hussein Alnajar | Jesse Fox | Wael Al Zoughbi | Troy Kane | L. Keefer | Aanavi Karandikar | Ellen L Verner | Manish A. Shah | Murtaza S. Malbari | Daniel Bockelman | Emily Patchell | Jesse M. Fox
[1] D. Schadendorf,et al. The predictive and prognostic significance of cell‐free DNA concentration in melanoma , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.
[2] M. Rubin,et al. Fusions involving BCOR and CREBBP are rare events in infiltrating glioma , 2020, Acta Neuropathologica Communications.
[3] E. Schuuring,et al. The potential of combined mutation sequencing of plasma circulating cell‐free DNA and matched white blood cells for treatment response prediction , 2020, Molecular oncology.
[4] L. Jahangiri,et al. Assessing the Concordance of Genomic Alterations between Circulating-Free DNA and Tumour Tissue in Cancer Patients , 2019, Cancers.
[5] David R. Riley,et al. Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade , 2019, Clinical Cancer Research.
[6] K. Pantel,et al. Liquid biopsy in the era of immune-oncology. Is it ready for prime-time use for cancer patients? , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] Catalin C. Barbacioru,et al. Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel , 2019, Clinical Cancer Research.
[8] Hongyu Zhao,et al. Next-generation sequencing in liquid biopsy: cancer screening and early detection , 2019, Human Genomics.
[9] R. Kurzrock,et al. Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies , 2019, Molecular Cancer Therapeutics.
[10] Tristan J. Lubinski,et al. Orthogonal Comparison of Four Plasma NGS Tests With Tumor Suggests Technical Factors are a Major Source of Assay Discordance. , 2019, JCO precision oncology.
[11] A. Thierry,et al. Recent advances in circulating nucleic acids in oncology. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] E. Felip,et al. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] Doron Lipson,et al. Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA , 2018, The Journal of molecular diagnostics : JMD.
[14] K. Spindler,et al. Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing , 2018, Translational oncology.
[15] Rachel Karchin,et al. A machine learning approach for somatic mutation discovery , 2018, Science Translational Medicine.
[16] K. Spindler,et al. Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] P. Laurent-Puig,et al. RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] C. García-Girón,et al. Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS , 2018, Clinical and Translational Oncology.
[19] C. Paweletz,et al. Cell-Free DNA in Oncology: Gearing up for Clinic , 2017, Annals of laboratory medicine.
[20] Y. Nishii,et al. Utility of Liquid Biopsy by Improved PNA‐LNA PCR Clamp Method for Detecting EGFR Mutation at Initial Diagnosis of Non–Small‐Cell Lung Cancer: Observational Study of 190 Consecutive Cases in Clinical Practice , 2017, Clinical lung cancer.
[21] B. Rini,et al. Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] Sam Angiuoli,et al. Direct detection of early-stage cancers using circulating tumor DNA , 2017, Science Translational Medicine.
[23] Marina N Nikiforova,et al. Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.
[24] Dorota Kwapisz,et al. The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer? , 2017, Annals of translational medicine.
[25] Marie-Cécile Le Deley,et al. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial , 2016, Clinical Cancer Research.
[26] Glen J Weiss,et al. Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making , 2015, OncoTargets and therapy.
[27] Eugenia G. Giannopoulou,et al. The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer , 2014, Nature Communications.
[28] Kai Ye,et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data , 2014, Bioinform..
[29] J. Tabernero,et al. Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer. , 2011, Future oncology.
[30] Francisco M. De La Vega,et al. Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing , 2010, Science Translational Medicine.
[31] Claude-Alain H. Roten,et al. Fast and accurate short read alignment with Burrows–Wheeler transform , 2009, Bioinform..